{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:44:11Z","timestamp":1792899851984,"version":"4.5.0"},"reference-count":54,"publisher":"American Chemical Society (ACS)","issue":"16","license":[{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA137078"],"award-info":[{"award-number":["1R01CA137078"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"University Cancer Research Fund, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We previously reported a potent small molecule Mer tyrosine kinase inhibitor UNC1062. However, its poor PK properties prevented further assessment in vivo. We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow. Kinome profiling versus more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an additional important target in acute myelogenous leukemia (AML), with pharmacologically useful selectivity versus other kinases examined.<\/jats:p>","DOI":"10.1021\/jm500749d","type":"journal-article","created":{"date-parts":[[2014,7,28]],"date-time":"2014-07-28T12:09:47Z","timestamp":1406549387000},"page":"7031-7041","source":"Crossref","is-referenced-by-count":165,"title":["<b>UNC2025<\/b>\n                    , a Potent\nand Orally Bioavailable\nMER\/FLT3 Dual Inhibitor"],"prefix":"10.1021","volume":"57","author":[{"given":"Weihe","family":"Zhang","sequence":"first","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"DeRyckere","sequence":"additional","affiliation":[{"name":"University of Colorado Denver , , , ,","place":["Aurora, Colorado, United States, 80045"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Hunter","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Stashko","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Minson","sequence":"additional","affiliation":[{"name":"University of Colorado Denver , , , ,","place":["Aurora, Colorado, United States, 80045"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Cummings","sequence":"additional","affiliation":[{"name":"University of Colorado Denver , , , ,","place":["Aurora, Colorado, United States, 80045"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjung","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Colorado Denver , , , ,","place":["Aurora, Colorado, United States, 80045"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor G.","family":"Glaros","sequence":"additional","affiliation":[{"name":"Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research , , , ,","place":["Frederick, Maryland, United States, 21702"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne L.","family":"Newton","sequence":"additional","affiliation":[{"name":"Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research , , , ,","place":["Frederick, Maryland, United States, 21702"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sather","sequence":"additional","affiliation":[{"name":"University of Colorado Denver , , , ,","place":["Aurora, Colorado, United States, 80045"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Kireev","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Janzen","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Shelton","family":"Earp","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]},{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K.","family":"Graham","sequence":"additional","affiliation":[{"name":"University of Colorado Denver , , , ,","place":["Aurora, Colorado, United States, 80045"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Frye","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]},{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2014,7,28]]},"reference":[{"issue":"8","key":"2026090121150844700_cit1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the Pharmaceutical\nIndustry Reduce Attrition Rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev.\nDrug Discovery"},{"issue":"1","key":"2026090121150844700_cit2","first-page":"57","article-title":"New Horizons\nin Drug Metabolism, Pharmacokinetics and Drug Discovery","volume":"16","author":"Palmer","year":"2003","journal-title":"Drug News Perspect."},{"issue":"17","key":"2026090121150844700_cit3a","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1021\/jm300846z","article-title":"Selective Class I Phosphoinositide\n3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines\nLeading to the Identification of a Clinical Candidate, AMG 511","volume":"55","author":"Norman","year":"2012","journal-title":"J. Med. Chem."},{"issue":"23","key":"2026090121150844700_cit3b","doi-asserted-by":"crossref","first-page":"10610","DOI":"10.1021\/jm301296t","article-title":"Design and\nOptimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol\nAcyltransferase 1 (DGAT1) Leading to a Clinical Candidate Dimethylpyrazinecarboxamide\nPhenylcyclohexylacetic Acid (AZD7687)","volume":"55","author":"Barlind","year":"2012","journal-title":"J. Med.\nChem."},{"issue":"15","key":"2026090121150844700_cit3c","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1021\/jm200592f","article-title":"Structure-Guided\nLead Optimization of Triazolopyrimidine-Ring Substituents Identifies\nPotent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors\nwith Clinical Candidate Potential","volume":"54","author":"Coteron","year":"2011","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026090121150844700_cit3d","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1039\/c2md20317k","article-title":"Metabolism-Guided Drug Design","volume":"4","author":"Stepan","year":"2013","journal-title":"MedChemComm"},{"issue":"13","key":"2026090121150844700_cit3e","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/jm300343m","article-title":"Mitigating Heterocycle Metabolism in Drug Discovery","volume":"55","author":"St Jean","year":"2012","journal-title":"J. Med. Chem."},{"issue":"17","key":"2026090121150844700_cit4","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.onc.1201039","article-title":"Identification of\nGas6 as a Ligand\nfor Mer, a Neural Cell Adhesion Molecule Related Receptor Tyrosine\nKinase Implicated in Cellular Transformation","volume":"14","author":"Chen","year":"1997","journal-title":"Oncogene"},{"key":"2026090121150844700_cit5a","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","article-title":"TAM Receptor\nTyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic\nTargeting in Human Cancer","volume":"100","author":"Linger","year":"2008","journal-title":"Adv. Cancer Res."},{"key":"2026090121150844700_cit5b","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/1535-7163.MCT-11-0116","article-title":"Targeting Axl and Mer Kinases in\nCancer","volume":"10","author":"Verma","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"2026090121150844700_cit6","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/1078-0432.CCR-05-2208","article-title":"Ectopic Expression\nof the Proto-Oncogene Mer in Pediatric\nT-Cell Acute Lymphoblastic Leukemia","volume":"12","author":"Graham","year":"2006","journal-title":"Clin. Cancer\nRes."},{"key":"2026090121150844700_cit7","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1038\/onc.2013.40","article-title":"Aberrant Mer Receptor Tyrosine Kinase Expression Contributes\nto Leukemogenesis in Acute Myeloid Leukemia","volume":"32","author":"Lee-Sherick","year":"2013","journal-title":"Oncogene"},{"key":"2026090121150844700_cit8","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1038\/onc.2012.355","article-title":"Mer or Axl Receptor\nTyrosine Kinase\nInhibition Promotes Apoptosis, Blocks Growth and Enhances Chemosensitivity\nof Human Non-Small Cell Lung Cancer","volume":"32","author":"Linger","year":"2013","journal-title":"Oncogene"},{"issue":"5","key":"2026090121150844700_cit9a","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1172\/JCI67816","article-title":"MERTK Receptor Tyrosine\nKinase Is a Therapeutic Target in Melanoma","volume":"123","author":"Schlegel","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"4","key":"2026090121150844700_cit9b","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pcmr.12110","article-title":"MERTK Controls Melanoma Cell Migration\nand Survival and Differentially Regulates Cell Behavior Relative to\nAXL","volume":"26","author":"Tworkoski","year":"2013","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"7","key":"2026090121150844700_cit10a","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/onc.2012.104","article-title":"Mer Receptor\nTyrosine Kinase Promotes Invasion and Survival in Glioblastoma Multiforme","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"issue":"38","key":"2026090121150844700_cit10b","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1038\/onc.2011.588","article-title":"Mer Receptor Tyrosine Kinase Inhibition\nImpedes Glioblastoma Multiforme Migration and Alters Cellular Morphology","volume":"31","author":"Rogers","year":"2012","journal-title":"Oncogene"},{"issue":"45","key":"2026090121150844700_cit11a","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1038\/sj.onc.1209633","article-title":"Lymphoblastic Leukemia\/Lymphoma in\nMice Overexpressing the Mer (MerTK) Receptor Tyrosine Kinase","volume":"25","author":"Keating","year":"2006","journal-title":"Oncogene"},{"issue":"5","key":"2026090121150844700_cit11b","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1535-7163.MCT-09-0707","article-title":"Inhibition of Mer\nand Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased\nApoptosis and Improved Chemosensitivity","volume":"9","author":"Keating","year":"2010","journal-title":"Mol.\nCancer Ther."},{"issue":"1","key":"2026090121150844700_cit11c","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1038\/bcj.2012.46","article-title":"Inhibition of MerTK Increases Chemosensitivity and\nDecreases Oncogenic Potential in T-Cell Acute Lymphoblastic Leukemia","volume":"3","author":"Brandao","year":"2013","journal-title":"Blood Cancer Journal"},{"key":"2026090121150844700_cit11d","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2013-01-478156","article-title":"Mer Receptor\nTyrosine Kinase Is a Therapeutic Target in Pre-B Cell Acute Lymphoblastic\nLeukemia","volume":"122","author":"Linger","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2026090121150844700_cit11e","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.18632\/oncotarget.1793","article-title":"MerTK Inhibition is a Novel Therapeutic\nApproach for Glioblastoma Multiforme","volume":"5","author":"Knubel","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"2026090121150844700_cit12a","first-page":"190","article-title":"FLT3 Internal\nTandem Duplication\nMutations in Adult Acute Myeloid Leukaemia Define a High-Risk Group","volume":"111","author":"Abu-Duhier","year":"2000","journal-title":"Br. J. Hamaetol."},{"issue":"6","key":"2026090121150844700_cit12b","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The Presence of a FLT3 Internal Tandem Duplication\nin Patients with Acute Myeloid Leukemia (AML) Adds Important Prognostic\nInformation to Cytogenetic Risk Group and Response to the First Cycle\nof Chemotherapy: Analysis of 854 Patients from the United Kingdom\nMedical Research Council AML 10 and 12 Trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2026090121150844700_cit13a","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with Acute\nMyeloid Leukemia and an Activating\nMutation in FLT3 Respond to a Small-Molecule FLT3 Tyrosine Kinase\nInhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2026090121150844700_cit13b","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1\nClinical Results with Tandutinib (MLN518), a Novel FLT3 Antagonist,\nIn Patients with Acute Myelogenous Leukemia or High-Risk Myelodysplastic\nSyndrome: Safety, Pharmacokinetics, And Pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2026090121150844700_cit13c","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A Phase 2 Trial of the FLT3 Inhibitor\nLestaurtinib (CEP701) as First-Line Treatment for Older Patients with\nAcute Myeloid Leukemia Not Considered Fit for Intensive Chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2026090121150844700_cit14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MOH.0000000000000022","article-title":"Will FLT3 inhibitors fulfill their promise in acute\nmeyloid leukemia?","volume":"21","author":"Pratz","year":"2014","journal-title":"Curr. Opin. Hematol."},{"key":"2026090121150844700_cit15a","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/ml200239k","article-title":"Discovery\nof Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric\nAcute Lymphoblastic Leukemia","volume":"3","author":"Liu","year":"2012","journal-title":"ACS Med. Chem.\nLett."},{"key":"2026090121150844700_cit15b","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejmech.2013.03.035","article-title":"UNC1062, a New and\nPotent Mer Inhibitor","volume":"65","author":"Liu","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"2026090121150844700_cit15c","doi-asserted-by":"crossref","first-page":"9683","DOI":"10.1021\/jm401387j","article-title":"Pseudo-Cyclization\nthrough Intramolecular Hydrogen Bond Enables Discovery of Pyridine\nSubstituted Pyrimidines as New Mer Kinase Inhibitors","volume":"56","author":"Zhang","year":"2013","journal-title":"J. Med. Chem."},{"issue":"23","key":"2026090121150844700_cit15d","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1021\/jm4013888","article-title":"Discovery\nof mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention\nof Thrombosis","volume":"56","author":"Zhang","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026090121150844700_cit16a","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jsb.2008.10.003","article-title":"Structural\nInsights into the Inhibited States of the Mer Receptor Tyrosine Kinase","volume":"165","author":"Huang","year":"2009","journal-title":"J. Struct Biol."},{"issue":"9","key":"2026090121150844700_cit16b","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1158\/0008-5472.CAN-09-3788","article-title":"Molecular Target Class Is Predictive of In vitro Response\nProfile","volume":"70","author":"Greshock","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"2026090121150844700_cit16c","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/jm800984v","article-title":"Fragment-Based Discovery of the Pyrazol-4-yl\nurea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora\nKinase Activity","volume":"52","author":"Howard","year":"2009","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026090121150844700_cit16d","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/jm801586s","article-title":"Discovery\nof N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide\n(BMS-777607), a Selective and Orally Efficacious Inhibitor of the\nMet Kinase Superfamily","volume":"52","author":"Schroeder","year":"2009","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026090121150844700_cit16e","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s10637-011-9699-0","article-title":"Foretinib (GSK1363089),\na Multi-Kinase Inhibitor of MET and VEGFRs, Inhibits Growth of Gastric\nCancer Cell Lines by Blocking Inter-Receptor Tyrosine Kinase Networks","volume":"30","author":"Kataoka","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"4","key":"2026090121150844700_cit16f","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10637-012-9912-9","article-title":"LY2801653 is an Orally Bioavailable\nMulti-Kinase Inhibitor with Potent Activity against MET, MST1R, and\nOther Oncoproteins, And Displays Anti-Tumor Activities in Mouse Xenograft\nModels","volume":"31","author":"Yan","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"12","key":"2026090121150844700_cit16g","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1021\/jm200112k","article-title":"Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one\n(MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer","volume":"54","author":"Katz","year":"2011","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026090121150844700_cit17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nchembio.296","article-title":"The Art\nof the Chemical Probe","volume":"6","author":"Frye","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"2026090121150844700_cit18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/co200039k","article-title":"Microwave-Assisted,\nDivergent Solution-Phase Synthesis of 1,3,6-Trisubstituted\nPyrazolo[3,4-d]pyrimidines","volume":"13","author":"Liu","year":"2011","journal-title":"ACS Comb. Sci."},{"issue":"9","key":"2026090121150844700_cit19","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1021\/ct300345m","article-title":"First-Principles\nCalculation of the Intrinsic Aqueous\nSolubility of Crystalline Druglike Molecules","volume":"8","author":"Palmer","year":"2012","journal-title":"J. Chem. Theory Comput."},{"issue":"11","key":"2026090121150844700_cit20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nbt.1581","article-title":"Comprehensive Characterization\nof\nCytochrome P450 Isozyme Selectivity Across Chemical Libraries","volume":"27","author":"Veith","year":"2009","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"2026090121150844700_cit21a","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1021\/jm00008a014","article-title":"Picornavirus Inhibitors: Trifluoromethyl\nSubstitution Provides a Global Protective Effect against Hepatic Metabolism","volume":"38","author":"Diana","year":"1995","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026090121150844700_cit21b","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/jm1013693","article-title":"Synopsis of Some Recent Tactical Application of Bioisosteres\nin Drug Design","volume":"54","author":"Meanwell","year":"2011","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026090121150844700_cit22","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1021\/ja036309a","article-title":"Strain Energy\nof Small Ring Hydrocarbons. Influence\nof C-H Bond Dissociation Energies","volume":"126","author":"Bach","year":"2004","journal-title":"J. Am. Chem.\nSoc."},{"issue":"2","key":"2026090121150844700_cit23","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bmcl.2011.12.030","article-title":"Pyrazolopyridine\nInhibitors of B-Raf V600E. Part 3: An Increase in Aqueous\nSolubility via the Disruption of Crystal Packing","volume":"22","author":"Wenglowsky","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"2026090121150844700_cit24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1021\/ci300403k","article-title":"Kinome-Wide Activity Modeling from Diverse Public High-Quality\nData Sets","volume":"53","author":"Schuu\u0308rer","year":"2013","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"2026090121150844700_cit25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/gtc.12022","article-title":"Activity-Based Kinase\nProfiling of Approved Tyrosine Kinase Inhibitors","volume":"18","author":"Kitagawa","year":"2013","journal-title":"Genes Cells"},{"issue":"11","key":"2026090121150844700_cit26","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive\nassay of kinase catalytic activity reveals features of kinase inhibitor\nselectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"2026090121150844700_cit27a","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0005-2744(69)90420-3","article-title":"Kinetics\nof the Reversible Inhibition\nof Enzyme-Catalysed Reactions by Tight-Binding Inhibitors","volume":"185","author":"Morrison","year":"1969","journal-title":"Biochim. Biophys. Acta"},{"key":"2026090121150844700_cit27b","first-page":"178","article-title":"Evaluation of Enzyme Inhibitors in Drug Discovery.\nA guide for Medicinal Chemists and Pharmacologists","volume":"46","author":"Copeland","year":"2005","journal-title":"Methods Biochem. Anal."},{"issue":"6","key":"2026090121150844700_cit28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chembiol.2011.04.011","article-title":"In Situ Kinase Profiling\nReveals Functionally Relevant Properties of Native Kinases","volume":"18","author":"Patricelli","year":"2011","journal-title":"Chem. Biol."},{"issue":"7","key":"2026090121150844700_cit29","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood-2004-07-2758","article-title":"RNAi-Induced down-Regulation of FLT3 Expression in\nAML Cell Lines Increases Sensitivity to MLN518","volume":"105","author":"Walters","year":"2005","journal-title":"Blood"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/jm500749d","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/57\/16\/7031\/12873243\/jm500749d.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/57\/16\/7031\/12873243\/jm500749d.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:15:21Z","timestamp":1788311721000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/57\/16\/7031\/1300382\/UNC2025-a-Potent-and-Orally-Bioavailable-MER-FLT3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,28]]},"references-count":54,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2014,7,28]]},"published-print":{"date-parts":[[2014,8,28]]}},"URL":"https:\/\/doi.org\/10.1021\/jm500749d","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,28]]}}}